Inherited bone marrow failure syndromes (IBMFS)

Introduction and Definition

• Inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of genetic disorders characterized by the decreased bone marrow production of one or more major hematopoietic lineages.
• These disorders can manifest initially as a single cytopenia (e.g., isolated neutropenia, anemia, or thrombocytopenia) or as global pancytopenia with a hypoplastic or aplastic bone marrow.
• IBMFS share three key clinical hallmarks:
  • bone marrow failure,
  • congenital physical anomalies, and
  • a marked predisposition to cancer, particularly myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and various solid tumors.

Pathophysiology

• The central pathophysiologic mechanism across most IBMFS is a low apoptotic threshold of mutant hematopoietic stem cells (HSCs), leading to accelerated apoptosis, premature senescence, and progressive depletion of bone marrow progenitors.
• These disorders are typically monogenic and arise from defects in critical, fundamental cellular pathways.
• Fanconi anemia is primarily driven by defects in DNA repair and homologous recombination, specifically involving the DNA interstrand cross-linking repair pathways.
• Dyskeratosis congenita is a telomeropathy resulting from pathogenic variants in genes encoding the telomerase complex and telomere-shelterin complex, leading to impaired telomere maintenance and extremely short telomeres.
• Diamond-Blackfan anemia and Shwachman-Diamond syndrome are classified as ribosomopathies, caused by defects in ribosome biosynthesis and ribosome assembly, respectively.

Major Syndromes and Clinical Features

Condition	Physical Findings	Hematologic Abnormalities	Associated Malignancies	Genetic Basis	Laboratory/Diagnostic Tests
Fanconi anemia	Short stature, low birth weight, microcephaly, microphthalmia, hearing loss, triangular face, micrognathia, high broad forehead, bulbous nose, low set ears, hypertelorism, cardiac anomalies, tracheoesophageal fistula, esophageal atresia, kidney/renal anomalies, radial ray defects (hypoplastic thumb/radius), hypoplastic thenar eminence, clinodactyly, café-au-lait spots, hyperpigmentation.	Progressive pancytopenia, macrocytosis (increased MCV), elevated HbF, acellular or hypocellular bone marrow; may present initially with isolated thrombocytopenia.	Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), squamous cell carcinomas (SCC) of head/neck, esophagus, vulva, anus, cervix, liver tumors (hepatocellular carcinoma), Wilms tumor.	AR, XLR, or AD; Pathogenic variants in 22 FANC genes (notably FANCA, FANCC, FANCG, FANCB, BRCA2/FANCD1, RB1).	Increased chromosomal breakage/fragility in clastogenic assay (diepoxybutane/DEB or mitomycin C/MMC), G2/M cell cycle arrest by flow cytometry, NGS (WES/WGS).
Diamond Blackfan anemia	Short stature, craniofacial anomalies (depressed nasal bridge, high-arched palate, cleft lip/palate, microcephaly), skeletal/upper limb anomalies (triphalangeal thumb, flat thenar eminence), absent radial pulse, cardiac, and genitourinary (absent/horseshoe kidney) abnormalities.	Pure red cell aplasia/failure, macrocytic anemia, reticulocytopenia, paucity of bone marrow erythroid precursors; occasionally neutropenia, thrombocytosis, or thrombocytopenia.	Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), colon/colorectal carcinoma, osteogenic sarcoma, female genital (breast) cancers.	AD (mostly) or XLR (GATA1, TSR2); Mutations in ribosomal protein genes (RPS19, RPL5, RPL11, RPS10, RPS24, RPS26).	Increased erythrocyte adenosine deaminase (eADA) activity, macrocytosis, elevated HbF, bone marrow aspirate showing paucity of erythroid precursors, normal chromosome breakage test.
Shwachman Diamond syndrome	Exocrine pancreatic insufficiency (fat malabsorption, steatorrhea, diarrhea), failure to thrive, short stature, skeletal abnormalities (metaphyseal dysostosis, rib cage abnormalities), neurodevelopmental delay.	Neutropenia (chronic or intermittent), anemia, thrombocytopenia, progression to pancytopenia and bone marrow failure; hypocellular bone marrow.	Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) (8.1% incidence at 10 years; up to 30% risk).	AR (SBDS, DNAJC21, EFL1) or AD (SRP54); also associated with abnormalities of chromosome 7.	Low serum isoamylase, low serum trypsinogen, fecal elastase reduction, pancreatic ultrasound (lipomatosis), low B cells, abnormal T-cell proliferation, genetic analysis.
Dyskeratosis congenita	Mucocutaneous triad (lacy reticular skin pigmentation, nail dysplasia/dystrophy, oral leukoplakia), pulmonary fibrosis, esophageal stenosis/webs, liver fibrosis, short stature, epiphora, early graying, lymphedema, ectodermal dysplasia.	Progressive bone marrow failure (pancytopenia), macrocytosis (high MCV), elevated HbF, acellular or hypocellular bone marrow; cytopenias may present at later ages.	Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), solid tumors (SCC of head and neck, skin, GI tract, anorectal adenocarcinoma).	XLR (DKC1), AD (TINF2, TERC, TERT, RTEL1, ACD), or AR (NHP2, NOP10); mutations in telomere maintenance genes.	Very short telomeres measured by flow-FISH (diagnostic hallmark), genetic sequencing (NGS/WES).
Congenital amegakaryocytic thrombocytopenia (CAMT)	Petechial rash, bruising, bleeding, intracranial hemorrhage; occasionally neurologic (cerebral/cerebellar atrophy), cardiac, orthopedic, renal anomalies, or microcephaly; often no physical anomalies at birth.	Severe isolated neonatal thrombocytopenia, absent or greatly reduced megakaryocytes in bone marrow; progression to pancytopenia/severe aplastic anemia by childhood.	Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML).	AR (MPL, THPO) or AD (HOXA11, MECOM); pathogenic variants in MPL (TPO receptor gene).	Bone marrow aspirate/biopsy showing absence of megakaryocytes, elevated plasma thrombopoietin (TPO) levels, MPL gene sequencing.

Other Notable Syndromes

• Thrombocytopenia-Absent Radius (TAR) Syndrome: Characterized by bilateral absent radii but with present thumbs, alongside severe thrombocytopenia that often improves after the first year of life.
• Severe Congenital Neutropenia (SCN): Includes disorders like Kostmann syndrome (HAX1 mutation) and ELANE mutations, presenting with severe bacterial infections and a maturation arrest of myelopoiesis at the promyelocyte stage.
• GATA2-Related Disorders: Autosomal dominant mutations causing immunodeficiency (MonoMAC syndrome), lymphedema (Emberger syndrome), and a high predisposition to primary MDS and AML.

Diagnostic Approach

• A detailed family history, history of medication or toxin exposure, and a thorough physical examination looking for specific congenital anomalies must be performed for any child presenting with cytopenias.
• Initial laboratory evaluation should include a complete blood count with reticulocyte count, peripheral blood smear, mean corpuscular volume (MCV), and fetal hemoglobin (HbF) levels.
• Bone marrow aspiration and trephine biopsy are essential to assess overall cellularity, evaluate for multilineage dysplasia, and perform cytogenetic studies to rule out MDS or leukemia.
• Specific screening tests include the chromosomal breakage assay (using clastogens like diepoxybutane or mitomycin C) for Fanconi anemia.
• Telomere length measurement via flow-FISH is utilized to diagnose dyskeratosis congenita.
• Erythrocyte adenosine deaminase (eADA) activity is typically elevated in Diamond-Blackfan anemia.
• Comprehensive genetic testing, including next-generation sequencing (NGS) panels for known IBMFS genes or whole-exome sequencing, is increasingly the standard of care to establish a definitive molecular diagnosis.

Management

• Supportive care is a mainstay of treatment, utilizing judicious, leukocyte-depleted, irradiated red blood cell and platelet transfusions only when clinically indicated to prevent severe alloimmunization and iron overload.
• Corticosteroids (e.g., prednisone) are the primary medical therapy for Diamond-Blackfan anemia, inducing a reticulocyte response in approximately 80% of patients.
• Androgen therapy (e.g., oxymetholone or danazol) can stimulate hematopoiesis and is effective in improving blood counts in about 50% of patients with Fanconi anemia and Dyskeratosis congenita.
• Cytokine therapy with Granulocyte Colony-Stimulating Factor (G-CSF) is utilized to manage severe neutropenia in SCN, SDS, and occasionally FA, though it must be monitored closely due to the risk of promoting leukemic transformation.
• Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the bone marrow failure, MDS, and leukemia associated with IBMFS.
• Preparative regimens for HSCT must frequently employ reduced-intensity conditioning (avoiding radiation and high-dose alkylating agents) due to the exquisite sensitivity of patients (especially those with FA and DC) to DNA-damaging therapies.
• Rigorous, lifelong cancer surveillance is mandatory, including regular bone marrow evaluations for clonal evolution, screening for head/neck and gynecologic squamous cell carcinomas, and monitoring of liver and endocrine function.